Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 10/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 0.56 |
| ▸ | APP | P05067 | 3/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | MELK | Q14680 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.41 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422651 | 0.85 | SMN1; SMN2 (0.48) | CDK5CDK5R1APPTDO2MAPT | |
| SCHEMBL1421592 | 0.85 | TDO2 (0.53) | APPTDO2MAPT | |
| SCHEMBL1420994 | 0.84 | CYP19A1 (0.52) | CDK5CDK5R1APPTDO2MAPT | |
| SCHEMBL13577803 | 0.84 | MAPT (0.44) | CDK5CDK5R1APPTDO2RIPK1 | |
| SCHEMBL1483699 | 0.82 | KDM4E (0.57) | APPRIPK1MAPT | |
| SCHEMBL1421172 | 0.81 | CYP19A1 (0.58) | CDK5CDK5R1RIPK1MAPT | |
| SCHEMBL1484054 | 0.79 | CDK5 (0.59) | CDK5CDK5R1RIPK1 | |
| SCHEMBL1484223 | 0.77 | ITK (0.48) | APPTDO2MAPT | |
| SCHEMBL1420991 | 0.76 | MAPT (0.43) | APPTDO2MAPT | |
| SCHEMBL13577807 | 0.76 | MAPT (0.41) | CDK5CDK5R1APPTDO2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101636395-A | Novel 2-heteroaryl substituted indoles 695 | ASTRAZENECA AB | 2010-01-27 | — | — | CN | claimed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| CN-101636395-A | Novel 2-heteroaryl substituted indoles 695 | ASTRAZENECA AB | 2010-01-27 | — | — | CN | disclosed |
| EP-2121655-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | APP, IDO2, IDO1 | CDK5 292/4885CDK5R1 788/4885APP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.